182 related articles for article (PubMed ID: 37771696)
1. The incidence of hepatocellular carcinoma and clearance of hepatitis B surface for CHB patients in the indeterminate phase: a systematic review and meta-analysis.
Liu M; Zhao T; Zhang Y; Zhang AM; Geng J; Xia X
Front Cell Infect Microbiol; 2023; 13():1226755. PubMed ID: 37771696
[TBL] [Abstract][Full Text] [Related]
2. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.
Song A; Wang X; Lu J; Jin Y; Ma L; Hu Z; Zheng Y; Shen C; Chen X
J Viral Hepat; 2021 Apr; 28(4):601-612. PubMed ID: 33455067
[TBL] [Abstract][Full Text] [Related]
3. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance.
Liu F; Wang XW; Chen L; Hu P; Ren H; Hu HD
Aliment Pharmacol Ther; 2016 Jun; 43(12):1253-61. PubMed ID: 27117732
[TBL] [Abstract][Full Text] [Related]
4. Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis.
Anderson RT; Choi HSJ; Lenz O; Peters MG; Janssen HLA; Mishra P; Donaldson E; Westman G; Buchholz S; Miller V; Hansen BE
Clin Gastroenterol Hepatol; 2021 Mar; 19(3):463-472. PubMed ID: 32473348
[TBL] [Abstract][Full Text] [Related]
5. Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis.
Song A; Lin X; Lu J; Ren S; Cao Z; Zheng S; Hu Z; Li H; Shen C; Chen X
Front Immunol; 2021; 12():779347. PubMed ID: 34804072
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and meta-analysis: Development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis e antigen seroconversion.
Zhou TC; Lai X; Feng MH; Tang Y; Zhang L; Wei J
J Viral Hepat; 2018 Oct; 25(10):1172-1179. PubMed ID: 29741285
[TBL] [Abstract][Full Text] [Related]
7. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
Lee HW; Lee JI; Kim S; Kim S; Chang HY; Lee KS
BMC Gastroenterol; 2020 Apr; 20(1):113. PubMed ID: 32305059
[TBL] [Abstract][Full Text] [Related]
8. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Huang DQ; Tran A; Yeh ML; Yasuda S; Tsai PC; Huang CF; Dai CY; Ogawa E; Ishigami M; Ito T; Kozuka R; Enomoto M; Suzuki T; Yoshimaru Y; Preda CM; Marin RI; Sandra I; Tran S; Quek SXZ; Khine HHTW; Itokawa N; Atsukawa M; Uojima H; Watanabe T; Takahashi H; Inoue K; Maeda M; Hoang JK; Trinh L; Barnett S; Cheung R; Lim SG; Trinh HN; Chuang WL; Tanaka Y; Toyoda H; Yu ML; Nguyen MH
Hepatology; 2023 Nov; 78(5):1558-1568. PubMed ID: 37184202
[TBL] [Abstract][Full Text] [Related]
9. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis.
Wong YJ; Nguyen VH; Yang HI; Li J; Le MH; Wu WJ; Han NX; Fong KY; Chen E; Wong C; Rui F; Xu X; Xue Q; Hu XY; Leow WQ; Goh GB; Cheung R; Wong G; Wong VW; Yu MW; Nguyen MH
Clin Mol Hepatol; 2023 Jul; 29(3):705-720. PubMed ID: 37157776
[TBL] [Abstract][Full Text] [Related]
10. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis.
Yeo YH; Ho HJ; Yang HI; Tseng TC; Hosaka T; Trinh HN; Kwak MS; Park YM; Fung JYY; Buti M; RodrÃguez M; Treeprasertsuk S; Preda CM; Ungtrakul T; Charatcharoenwitthaya P; Li X; Li J; Zhang J; Le MH; Wei B; Zou B; Le A; Jeong D; Chien N; Kam L; Lee CC; Riveiro-Barciela M; Istratescu D; Sriprayoon T; Chong Y; Tanwandee T; Kobayashi M; Suzuki F; Yuen MF; Lee HS; Kao JH; Lok AS; Wu CY; Nguyen MH
Gastroenterology; 2019 Feb; 156(3):635-646.e9. PubMed ID: 30342034
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study.
Fwu CW; Chien YC; Kirk GD; Nelson KE; You SL; Kuo HS; Feinleib M; Chen CJ
J Natl Cancer Inst; 2009 Jul; 101(14):1019-27. PubMed ID: 19535774
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA).
Coffin CS; Haylock-Jacobs S; Doucette K; Ramji A; Ko HH; Wong DK; Elkhashab M; Bailey R; Uhanova J; Minuk G; Tsoi K; Wong A; Ma MM; Tam E; Brahmania M; Nudo C; Zhu J; Lowe CF; Osiowy C; Lethebe BC; Congly SE; Chan EKH; Villasis-Keever A; Sbarigia U; Cooper CL; Fung S
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560672
[TBL] [Abstract][Full Text] [Related]
13. Association between Hepatitis B Surface Antigen Levels and the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection: Systematic Review and Meta-Analysis.
Thi Vo T; Poovorawan K; Charoen P; Soonthornworasiri N; Nontprasert A; Kittitrakul C; Phumratanaprapin W; Tangkijvanich P
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2239-2246. PubMed ID: 31450890
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD
World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376
[TBL] [Abstract][Full Text] [Related]
16. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients.
Liang LY; Wong VW; Toyoda H; Tse YK; Yip TC; Yuen BW; Tada T; Kumada T; Lee HW; Lui GC; Chan HL; Wong GL
J Gastroenterol; 2020 Sep; 55(9):899-908. PubMed ID: 32556643
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B e antigen and the risk of hepatocellular carcinoma.
Yang HI; Lu SN; Liaw YF; You SL; Sun CA; Wang LY; Hsiao CK; Chen PJ; Chen DS; Chen CJ;
N Engl J Med; 2002 Jul; 347(3):168-74. PubMed ID: 12124405
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus core-related antigen (HBcrAg) as a prognostic marker for the development of hepatocellular carcinoma: A mini systematic review of the literature.
Afifi AM; Elgenidy A; Hashim M; Awad AK; Jalal PK
Rev Med Virol; 2022 Nov; 32(6):e2353. PubMed ID: 35441759
[TBL] [Abstract][Full Text] [Related]
19. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma.
Chu CM
J Gastroenterol Hepatol; 2000 May; 15 Suppl():E25-30. PubMed ID: 10921378
[TBL] [Abstract][Full Text] [Related]
20. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
